nach oben

06.05.2024 | Original Research

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study

verfasst von: Helen Tesfaye, PharmD, MSc, Katherine M. Wang, MD, MS, Luke E. Zabotka, BA, Deborah J. Wexler, MD, MSc, Niklas Schmedt, DrPH, Lisette Koeneman, MD, Leo Seman, MD, PhD, Julie M. Paik, MD, ScD, MPH, Elisabetta Patorno, MD, DrPH

Erschienen in: Journal of General Internal Medicine

Einloggen, um Zugang zu erhalten

Abstract

Background

Hyperuricemia is frequently observed in patients with type 2 diabetes (T2D) and is associated with increased risk of gout and cardiovascular disease (CVD). Empagliflozin lowers serum urate levels by enhancing its urinary excretion.

Objective

To compare initiators of empagliflozin vs dipeptidyl peptidase-4 inhibitor (DPP4i) and initiators of empagliflozin vs glucagon-like peptide-1 receptor agonist (GLP-1RA) with respect to the risk of incident gout events.

Design and Participants

Using three claims-based datasets from 08/2014 to 09/2019, we generated two cohorts (cohort 1: empagliflozin vs DPP4i; cohort 2: empagliflozin vs GLP-1RA) of adult patients with T2D and without prior history of gout or gout-specific medication dispensing separately in each dataset. To assess the risk of incident gout, we estimated hazard ratios (HR) and rate differences (RD) per 1000 person-years (PY) with their 95% confidence intervals (CI) before and after 1:1 propensity score (PS) matching adjusting for 141 baseline covariates.

Key Results

We identified 102,262 pairs of 1:1 propensity score-matched adults in cohort 1 and 131,216 pairs in cohort 2. Over a mean follow-up period of 8 months on treatment, the risk of gout was lower in patients initiating empagliflozin compared to DPP4i (HR = 0.69: 95% CI (0.60–0.79); RD = − 2.27: 95% CI (− 3.08, 1.46)) or GLP-1RA (HR = 0.83: 95% CI (0.73–0.94); RD = − 0.99: 95% CI (− 1.66, − 0.32)). Results were consistent across subgroups (sex, age, body mass index, chronic kidney disease, heart failure, cardiovascular disease, and concurrent diuretic use) and sensitivity analyses.

Conclusions

Among adults with T2D, the initiation of empagliflozin vs a DPP4i or GLP-1RA was associated with lower risk of incident gout, complementing results from a post hoc analysis of the EMPA-REG OUTCOME trial and previously published observational research focusing on the sodium-glucose co-transporter-2 inhibitor class in more narrowly defined study populations.

Nur mit Berechtigung zugänglich

Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–772. https://doi.org/10.1038/s41569-020-0406-8.CrossRefPubMed

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73–79. https://doi.org/10.1097/med.0000000000000311.CrossRefPubMedPubMedCentral

Verma S. Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits. Am J Cardiol. 2019;124:S36–S44. https://doi.org/10.1016/j.amjcard.2019.10.028.CrossRefPubMed

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.CrossRefPubMed

Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704. https://doi.org/10.1016/s2213-8587(18)30141-4.CrossRefPubMed

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744.CrossRefPubMed

Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462. https://doi.org/10.1111/dom.13101.CrossRefPubMed

Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24(1):135–141. https://doi.org/10.1111/dom.14559.CrossRefPubMed

Li J, Woodward M, Perkovic V, et al. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail. 2020;8(1):57–66. https://doi.org/10.1016/j.jchf.2019.08.004.CrossRefPubMed

10.

Li J, Neal B, Perkovic V, et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020;98(3):769–777. https://doi.org/10.1016/j.kint.2020.04.051.CrossRefPubMed

11.

Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361–362. https://doi.org/10.2337/dc07-1276.CrossRefPubMed

12.

Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796–803. https://doi.org/10.1053/j.ajkd.2008.12.021.CrossRefPubMedPubMedCentral

13.

Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221–2228. https://doi.org/10.1093/ndt/gft029.CrossRefPubMedPubMedCentral

14.

Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380–390. https://doi.org/10.1038/s41584-020-0441-1.CrossRefPubMed

15.

Safiri S, Kolahi AA, Cross M, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990–2017: a systematic analysis of the global burden of disease study 2017. Arthritis Rheumatol. 72(11):1916–1927. https://doi.org/10.1002/art.41404.

16.

White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–1210. https://doi.org/10.1056/NEJMoa1710895.CrossRefPubMed

17.

Patorno E, Najafzadeh M, Pawar A, et al. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab. 2020;3(1):e00103. https://doi.org/10.1002/edm2.103.CrossRefPubMed

18.

Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S111–S124. https://doi.org/10.2337/dc21-S009.

19.

Tonneijck L, Muskiet MHA, Smits MM, et al. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018;20(5):1235–1245. https://doi.org/10.1111/dom.13223.CrossRefPubMedPubMedCentral

20.

Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113. https://doi.org/10.1016/S2213-8587(17)30412-6.CrossRefPubMed

21.

MacFarlane LA, Liu CC, Solomon DH, Kim SC. Validation of claims-based algorithms for gout flares. Pharmacoepidemiol Drug Saf. 2016;25(7):820-6. https://doi.org/10.1002/pds.4044.CrossRefPubMedPubMedCentral

22.

Dehlin M, Stasinopoulou K, Jacobsson L. Validity of gout diagnosis in Swedish primary and secondary care - a validation study. BMC Musculoskelet Disord. 2015;16(1):149. https://doi.org/10.1186/s12891-015-0614-2.CrossRefPubMedPubMedCentral

23.

Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172(3):186–194. https://doi.org/10.7326/M19-2610.CrossRefPubMedPubMedCentral

24.

Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021;32(12):2994–3015. https://doi.org/10.1681/ASN.2021070988.CrossRefPubMedPubMedCentral

25.

Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–763. https://doi.org/10.7326/0003-4819-127-8_part_2-199710151-00064.CrossRefPubMed

26.

Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM. Implications of the propensity score matching paradox in pharmacoepidemiology. Am J Epidemiol. 2018;187(9):1951–1961. https://doi.org/10.1093/aje/kwy078.CrossRefPubMedPubMedCentral

27.

Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–584. https://doi.org/10.1016/j.cjca.2017.12.005.CrossRefPubMed

28.

Suijk DLS, van Baar MJB, van Bommel EJM, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17(5):663–671. https://doi.org/10.2215/CJN.11480821.CrossRefPubMedPubMedCentral

29.

Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022;43(36):3435–3446. https://doi.org/10.1093/eurheartj/ehac320.CrossRefPubMedPubMedCentral

30.

Li J, Badve SV, Zhou Z, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1(4):e220–e228. https://doi.org/10.1016/S2665-9913(19)30078-5.CrossRefPubMed

31.

McCormick N, Yokose C, Wei J, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations : a general population cohort study. Ann Intern Med. 2023. https://doi.org/10.7326/M23-0724.CrossRefPubMed

32.

Chung MC, Hung PH, Hsiao PJ, et al. Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in taiwan. JAMA Netw Open. 2021;4(11):e2135353. https://doi.org/10.1001/jamanetworkopen.2021.35353.CrossRefPubMedPubMedCentral

33.

Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870. https://doi.org/10.1001/jamaoncol.2019.1870.CrossRefPubMedPubMedCentral

34.

Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. https://doi.org/10.1186/s13063-015-1023-4.CrossRefPubMedPubMedCentral

Titel: Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study
verfasst von: Helen Tesfaye, PharmD, MSc
Katherine M. Wang, MD, MS
Luke E. Zabotka, BA
Deborah J. Wexler, MD, MSc
Niklas Schmedt, DrPH
Lisette Koeneman, MD
Leo Seman, MD, PhD
Julie M. Paik, MD, ScD, MPH
Elisabetta Patorno, MD, DrPH
Publikationsdatum: 06.05.2024
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-024-08793-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study

Abstract

Background

Objective

Design and Participants

Key Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Design and Participants

Key Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin